Twist Bioscience reported revenue up 22% to $459.4 million for fiscal 2026 from $376.6 million, while net loss widened to $130.2 million from $77.7 million.
TWST · Twist Bioscience Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Twist Bioscience expects fiscal 2027 revenue of $550 million to $560 million, approximately 21% growth at the midpoint, including $100 million of AI drug discovery revenue. Fiscal 2026 revenue was $459.4 million, up 22%.
Twist Bioscience reported fiscal 2026 revenue of $459.4 million, an increase of 22%, and fourth-quarter revenue of $126.6 million, an increase of 28%. Fiscal 2027 revenue guidance is $550 million to $560 million, including first-quarter guidance of $130 million to $132 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Nov 12, 2026TL;DR. Twist delivered 22% fiscal 2026 revenue growth, 175% AI drug-discovery growth, gross-margin expansion and a 15th consecutive quarter of sequential growth, and guides to $550-$560 million of fiscal 2027 revenue with positive adjusted EBITDA. Risks include the fiscal 2026 net loss of $130.2 million, continued full-year adjusted-EBITDA losses, deployment-related margin pressure, uncertain AI demand, competitive obsolescence risk and supplier concentration.
- + AI drug discovery revenue grew 175% to $59.1 million and orders more than doubled in fiscal 2026 new
- + Fiscal 2026 revenue increased 22% to $459.4 million new
- + Fourth-quarter revenue grew 28% to $126.6 million, marking a 15th consecutive quarter of sequential growth new
- + Fiscal 2026 gross margin improved to 52.4% from 50.7% new
- + Fiscal 2027 revenue guidance is $550 million to $560 million, representing approximately 21% growth at the midpoint new
- + Management expects adjusted EBITDA to be positive for fiscal 2027 new
- − Fiscal 2026 net loss widened to $130.2 million from $77.7 million new
- − Fiscal 2026 adjusted EBITDA remained negative at $35.9 million new
- − Fiscal 2027 capacity investments are expected to create a two-to-three-point gross-margin headwind new
- − Demand for AI-enabled drug discovery may not continue at current rates new
- − Rapid technology changes and competition could render Twist's products obsolete or noncompetitive new
- − Twist depends on one supplier for a critical component new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 2018 ESPP expense | $2.1M | year ended September 30, 2026 filing | — |
| Customers served | 4,100 | fiscal year 2026 filing | — |
| Employer matching contributions expense | $3.5M | year ended September 30, 2026 filing | — |
| Genes shipped | 1.34M | Year ended September 30, 2026 filing | — |
| revenue generated from customers located outside of the United States | 41% | fiscal year ended September 30, 2026 filing | -2.4% |
|
|
|||
| revenue recognized over time | $58.7M | fiscal 2026 filing | — |
| revenue recognized over time as a share of total revenue | 13% | fiscal 2026 filing | — |
| Weighted-average remaining lease term (in years) - operating leases | 13.92 | Year ended September 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | -$11.3M | the third quarter of fiscal 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net (loss) income -35.05M
-1.5M Interest income
+311K Income tax expense
+6.78M Depreciation and amortization
+0K Litigation settlement costs, net of recoveries
+0K Gain on sale of business
-40K Other (income) expense, net
+18.18M Stock-based compensation expense
= Adjusted EBITDA -11.33M
|
|||
| DNA Synthesis and Protein Solutions (DSPS) revenue | $56.6M | the third quarter of fiscal 2026 | +38.8% |
|
|
|||
| Gross margin | 52.8% | the third quarter of fiscal 2026 | — |
| NGS Applications (NGS) revenue | $61.8M | the third quarter of fiscal 2026 | +11.8% |
|
|
|||
| Number of customers who purchased products | 2,664 | the three months ended June 30, 2026 filing | — |
| Number of genes shipped | 369K | the three months ended June 30, 2026 filing | — |
| Physically shipped genes | 369,000 | the third quarter of fiscal 2026 | — |
| Shipped products to customers | 2,650 | the third quarter of fiscal 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TWST
this stock
Twist Bioscience Corp
|
$7.93B | +266.8% | +22.0% | — | 14.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TWST | -5.1% | -22.0% | +74.0% | -23.8% | +266.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -1.2% | -16.4% | +77.5% | -20.5% | +259.7% |